Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests

Inter-test concordance between the MammaPrint and the EndoPredict tests used to predict the risk of recurrence in breast cancer was evaluated in 94 oestrogen receptor-positive, HER2-negative breast cancers. We correlated histopathological data with clinical risk estimation as defined in the MINDACT...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahn, Stephan Wenzel, Bösl, Andreas, Tsybrovskyy, Oleksiy, Gruber-Rossipal, Christine, Helfgott, Ruth, Fitzal, Florian, Knauer, Michael, Balic, Marija, Jasarevic, Zerina, Offner, Felix, Moinfar, Farid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283343/
https://www.ncbi.nlm.nih.gov/pubmed/32336753
http://dx.doi.org/10.1038/s41416-020-0838-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283343/
https://www.ncbi.nlm.nih.gov/pubmed/32336753
http://dx.doi.org/10.1038/s41416-020-0838-2

Ejemplares similares